Literature DB >> 1931609

The detection of phthalocyanine fluorescence in normal rat bladder wall using sensitive digital imaging microscopy.

A J Pope1, A J MacRobert, D Phillips, S G Bown.   

Abstract

The ability to detect photosensitisers in tissue at a microscopical level is important when studying photodynamic therapy (PDT) in both normal and malignant tissue. We have studied the fluorescence distribution of aluminium sulphonated phthalocyanine (A1SPc) in the normal rat bladder using a cooled CCD (charge coupled device) imaging system with computerised image processing. This system makes it possible to carry out a quantitative assessment of photosensitiser fluorescence in the various layers of the bladder wall. The highest fluorescence intensities were obtained within 1 h of intravenous administration but there was little selectivity of uptake between layers. A1SPc was eliminated from the deeper muscle layers more quickly than from the superficial layers of the bladder wall so that by 24 h a 4:1 ratio of fluorescence intensity was apparent which persisted at least until 72 h, although the absolute amount of photosensitiser declined. Following irradiation by red light (675 nm), photobleaching of the sensitiser in the deeper layers further increased this ratio. Direct absorption of A1SPc by the bladder wall following intravesical administration proved unreliable.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1931609      PMCID: PMC1977460          DOI: 10.1038/bjc.1991.417

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Aluminum sulfonated phthalocyanine distribution in rodent tumors of the colon, brain and pancreas.

Authors:  C J Tralau; H Barr; D R Sandeman; T Barton; M R Lewin; S G Bown
Journal:  Photochem Photobiol       Date:  1987-11       Impact factor: 3.421

2.  Dose measurements in photodynamic therapy of cancer.

Authors:  A E Profio; D R Doiron
Journal:  Lasers Surg Med       Date:  1987       Impact factor: 4.025

3.  Effect of bleaching of porphyrin sensitizers during photodynamic therapy.

Authors:  J Moan
Journal:  Cancer Lett       Date:  1986-10       Impact factor: 8.679

4.  Photobleaching of porphyrins used in photodynamic therapy and implications for therapy.

Authors:  T S Mang; T J Dougherty; W R Potter; D G Boyle; S Somer; J Moan
Journal:  Photochem Photobiol       Date:  1987-04       Impact factor: 3.421

5.  Uptake and localization of HPD and "active fraction" in tissue culture and in serially biopsied human tumors.

Authors:  M W Berns; M Hammer-Wilson; R J Walter; W Wright; M H Chow; M Nahabedian; A Wile
Journal:  Prog Clin Biol Res       Date:  1984

6.  The morphological and functional changes in rat bladder following photodynamic therapy with phthalocyanine photosensitization.

Authors:  A J Pope; S G Bown
Journal:  J Urol       Date:  1991-05       Impact factor: 7.450

7.  Photodynamic therapy in the management of resistant lower urinary tract carcinoma.

Authors:  U O Nseyo; T J Dougherty; L Sullivan
Journal:  Cancer       Date:  1987-12-15       Impact factor: 6.860

8.  Zinc tetrasulphophthalocyanine as a photodynamic sensitizer for biomolecules.

Authors:  J D Spikes; J C Bommer
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1986-07

9.  Photodynamic therapy with porphyrin and phthalocyanine sensitisation: quantitative studies in normal rat liver.

Authors:  S G Bown; C J Tralau; P D Smith; D Akdemir; T J Wieman
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

10.  Photodynamic therapy in the normal rat colon with phthalocyanine sensitisation.

Authors:  H Barr; C J Tralau; A J MacRobert; N Krasner; P B Boulos; C G Clark; S G Bown
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

View more
  10 in total

1.  Experimental studies to assess the potential of photodynamic therapy for the treatment of bronchial carcinomas.

Authors:  S G Smith; J Bedwell; A J MacRobert; M H Griffiths; S G Bown; M R Hetzel
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

2.  Possible advantages of aluminum-chloro-tetrasulfonated phthalocyanine over hematoporphyrin derivative as a photosensitizer in photodynamic therapy.

Authors:  K Koshida; H Hisazumi; K Komatsu; A Hirata; T Uchibayashi
Journal:  Urol Res       Date:  1993

Review 3.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

4.  Comparison of two routes of photosensitizer administration for photodynamic therapy of bladder cancer.

Authors:  R Bachor; R Hautmann; T Hasan
Journal:  Urol Res       Date:  1994

5.  Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.

Authors:  J C Bremner; G E Adams; J K Pearson; J M Sansom; I J Stratford; J Bedwell; S G Bown; A J MacRobert; D Phillips
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

6.  Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phthalocyanine and 5-aminolaevulinic acid.

Authors:  C S Loh; J Bedwell; A J MacRobert; N Krasner; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

7.  The effect of aminolaevulinic acid-induced, protoporphyrin IX-mediated photodynamic therapy on the cremaster muscle microcirculation in vivo.

Authors:  J Leveckis; N J Brown; M W Reed
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

8.  In vivo fluorescence kinetics and localisation of aluminum phthalocyanine disulphonate in an autologous tumour model.

Authors:  M J Witjes; O C Speelman; P G Nikkels; C A Nooren; J M Nauta; B van der Holt; H L van Leengoed; W M Star; J L Roodenburg
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

9.  The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells.

Authors:  K Berg; H Anholt; O Bech; J Moan
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.

Authors:  C S Loh; A J MacRobert; J Bedwell; J Regula; N Krasner; S G Bown
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.